NYSEAMERICAN:IBIO iBio (IBIO) Stock Forecast, Price & News $0.79 -0.03 (-3.67%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$0.77▼$0.8350-Day Range N/A52-Week Range$0.36▼$16.51Volume241,060 shsAverage Volume2.15 million shsMarket Capitalization$13.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About iBio (NYSEAMERICAN:IBIO) StockiBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.Read More Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Stock News HeadlinesJune 6, 2023 | finance.yahoo.comiBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development PipelineMay 26, 2023 | msn.comFrom Radiohead reimaginings to musical molluscs: Glasgow Jazz Festival broadens its horizonsJune 7, 2023 | UNKNOWN (Ad)The Stock That's Brining Lithium Back To America!The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S SoilMay 26, 2023 | msn.comFrom Radiohead reimaginings to musical moluscs: Glasgow Jazz Festival broadens its horizonsMay 18, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Ibio (IBIO), SeaStar Medical Holding (ICU) and Viking Therapeutics (VKTX)May 12, 2023 | msn.comiBio: Q3 Earnings InsightsMay 10, 2023 | marketwatch.comiBio Inc. stock falls Wednesday, underperforms marketMay 10, 2023 | marketwatch.comiBio Inc. stock falls Monday, underperforms marketJune 7, 2023 | UNKNOWN (Ad)The Stock That's Brining Lithium Back To America!The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S SoilMay 9, 2023 | finance.yahoo.comiBio to Participate in the JMP Securities Life Sciences ConferenceMay 4, 2023 | marketwatch.comiBio Inc. stock rises Tuesday, outperforms marketApril 23, 2023 | marketwatch.comiBio Inc. stock rises Friday, outperforms marketApril 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Kura Oncology (KURA) and Ibio (IBIO)April 13, 2023 | finance.yahoo.comPlasma Protease C1 Inhibitor Market size to grow by USD 1.7 billion from 2021 to 2026, Driven by the increasing R&D - TechnavioApril 13, 2023 | benzinga.comPlant-Based Biologics Market Is Expected to Generate $182.9 Million by 2031: Allied Market ResearchApril 4, 2023 | finance.yahoo.comiBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering PlatformApril 2, 2023 | finanznachrichten.deiBio, Inc.: iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo TestingApril 2, 2023 | benzinga.comiBio Announces Progression Of Anri-CCR8 Antibody Immuno-Oncology Program Into Preclinical In Vivo TestingMarch 31, 2023 | finance.yahoo.comiBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo TestingMarch 30, 2023 | americanbankingnews.comMartin Brenner Sells 5,213 Shares of iBio, Inc. (NYSEAMERICAN:IBIO) StockMarch 22, 2023 | reuters.comIBIO.C - | Stock Price & Latest News | ReutersFebruary 17, 2023 | investorplace.comWhy Is iBio (IBIO) Stock Up 124% Today?February 17, 2023 | benzinga.comWhy Nogin Shares Are Trading Higher By Around 77%; Here Are 20 Stocks Moving PremarketFebruary 16, 2023 | finance.yahoo.comiBio Announces MUC16 as its Latest Immune-Oncology Target ProgramFebruary 15, 2023 | investing.comJMP Securities Downgrades iBio, Inc. to Market PerformJanuary 5, 2023 | finance.yahoo.comiBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery EngineJanuary 2, 2023 | marketwatch.comWith 7% CAGR, Hereditary Angioedema Market 2023-2028 Find Out Essential Strategies To Expand The Business And Top Key Players | 93 Pages ReportSee More Headlines IBIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Company Calendar Last Earnings11/15/2021Today6/07/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IBIO Previous SymbolNASDAQ:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(979) 446-0027Fax302-356-1173Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,300,000.00 Net MarginsN/A Pretax Margin-11,133.67% Return on Equity-150.09% Return on Assets-79.33% Debt Debt-to-Equity Ratio0.04 Current Ratio1.22 Quick Ratio1.22 Sales & Book Value Annual Sales$2.38 million Price / Sales5.56 Cash FlowN/A Price / Cash FlowN/A Book Value$7.27 per share Price / Book0.11Miscellaneous Outstanding Shares16,800,000Free Float16,398,000Market Cap$13.24 million OptionableNot Optionable Beta-3.19 Key ExecutivesMartin B. BrennerChief Executive & Scientific OfficerMike JenkinsVice President-OperationsFelipe DuranCFO, Vice President-Financial Planning & AnalysisPhan DillonVice President, Head-Research & DevelopmentMatthew LuterVice President-Information TechnologyKey CompetitorsAeterna ZentarisNASDAQ:AEZSAprea TherapeuticsNASDAQ:APREEvelo BiosciencesNASDAQ:EVLONovelion TherapeuticsOTCMKTS:NVLNFSkye BioscienceOTCMKTS:SKYEView All CompetitorsInsiders & InstitutionsMartin BrennerSold 4,182 sharesTotal: $3,931.08 ($0.94/share)Armistice Capital LLCBought 525,644 shares on 5/16/2023Ownership: 4.249%State Street CorpBought 17,200 shares on 5/16/2023Ownership: 0.389%Susquehanna International Group LLPBought 15,600 shares on 5/16/2023Ownership: 0.000%Sabby Management LLCBought 3,491 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IBIO Stock - Frequently Asked Questions Should I buy or sell iBio stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares. View IBIO analyst ratings or view top-rated stocks. How were iBio's earnings last quarter? iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company earned $0.21 million during the quarter. When did iBio's stock split? Shares of iBio reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA). What is iBio's stock symbol? iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO." Who are iBio's major shareholders? iBio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.25%), BlackRock Inc. (1.12%), Bank of New York Mellon Corp (0.71%), Renaissance Technologies LLC (0.55%), State Street Corp (0.39%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Eastern Capital Ltd, Martin Brenner and Robert Matthew Lutz. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iBio's stock price today? One share of IBIO stock can currently be purchased for approximately $0.79. How much money does iBio make? iBio (NYSEAMERICAN:IBIO) has a market capitalization of $13.24 million and generates $2.38 million in revenue each year. How can I contact iBio? iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173. This page (NYSEAMERICAN:IBIO) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.